{"id":59262,"date":"2026-03-11T16:14:24","date_gmt":"2026-03-11T08:14:24","guid":{"rendered":"https:\/\/flcube.com\/?p=59262"},"modified":"2026-03-11T16:14:24","modified_gmt":"2026-03-11T08:14:24","slug":"fosun-pharmas-tenapanor-vteglea-issues-first-china-prescription-nhe3-inhibitor-targets-hyperphosphatemia-in-dialysis-patients","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59262","title":{"rendered":"Fosun Pharma’s Tenapanor (Vteglea) Issues First China Prescription \u2013 NHE3 Inhibitor Targets Hyperphosphatemia in Dialysis Patients"},"content":{"rendered":"\n

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.<\/strong> (SHA: 600196<\/a>, HKG: 2196<\/a>) announced the first prescription issuance<\/strong> for Tenapanor (trade name: Vteglea)<\/strong> in China, marking the commercial launch<\/strong> of the NHE3 inhibitor<\/strong> for serum phosphorus control in dialysis patients with chronic kidney disease (CKD)<\/strong>. Licensed from Ardelyx, Inc.<\/strong> in December 2017<\/strong>, the drug received NMPA approval in February 2025<\/strong> for patients with inadequate response or intolerance to phosphate binders<\/strong>, expanding Fosun’s nephrology portfolio<\/strong> into the hyperphosphatemia market<\/strong> serving China’s 400,000+ dialysis population<\/strong>.<\/p>\n\n\n\n

Commercial Launch Milestone<\/h2>\n\n\n\n
Element<\/th>Detail<\/th><\/tr><\/thead>
Product<\/strong><\/td>Tenapanor (Vteglea)<\/td><\/tr>
Drug Class<\/strong><\/td>Intestinal sodium\/hydrogen exchanger 3 (NHE3) inhibitor<\/td><\/tr>
Mechanism<\/strong><\/td>Tightens intercellular connections \u2192 reduces paracellular phosphate absorption \u2192 lowers blood phosphorus<\/td><\/tr>
Indication (China)<\/strong><\/td>Control serum phosphorus in CKD dialysis patients (inadequate response\/intolerance to phosphate binders)<\/td><\/tr>
License Origin<\/strong><\/td>Ardelyx, Inc. (U.S.) \u2013 December 2017 agreement<\/td><\/tr>
NMPA Approval<\/strong><\/td>February 2025<\/td><\/tr>
First Prescription<\/strong><\/td>10\u202fMar\u202f2026<\/td><\/tr>
Marketer<\/strong><\/td>Shanghai Fosun Pharmaceutical (SHA: 600196, HKG: 2196)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Regulatory History & Global Approvals<\/h2>\n\n\n\n
Region<\/th>Indication<\/th>Approval Date<\/th>Status<\/th><\/tr><\/thead>
U.S.<\/strong><\/td>Irritable bowel syndrome with constipation (IBS-C)<\/td>September 2019<\/td>Approved (Ibsrela brand)<\/td><\/tr>
Hong Kong<\/strong><\/td>IBS-C<\/td>November 2023<\/td>Approved<\/td><\/tr>
U.S.<\/strong><\/td>Hyperphosphatemia in CKD dialysis (add-on to binders)<\/td>October 2023<\/td>Approved (Xphozia brand)<\/td><\/tr>
China<\/strong><\/td>Hyperphosphatemia in CKD dialysis<\/td>February 2025<\/td>Approved (Vteglea brand)<\/td><\/tr>
Commercial Launch<\/strong><\/td>China hyperphosphatemia<\/td>March 2026<\/td>First prescription issued<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Context & Strategic Value<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
China CKD Burden<\/strong><\/td>100+ million CKD patients; 400,000+ on dialysis; hyperphosphatemia prevalence >80%<\/td><\/tr>
Standard of Care<\/strong><\/td>Phosphate binders (calcium acetate, sevelamer, lanthanum) \u2013 adherence challenges, GI side effects, pill burden<\/td><\/tr>
Tenapanor Differentiation<\/strong><\/td>Oral small molecule; novel mechanism vs. binders; reduces pill burden; addresses binder intolerance\/resistance<\/td><\/tr>
Fosun Portfolio Fit<\/strong><\/td>Complicates nephrology franchise (HLX316 in development); leverages hospital dialysis center relationships<\/td><\/tr>
Pricing Strategy<\/strong><\/td>Premium positioning justified by mechanism novelty; NRDL negotiation anticipated 2026-2027<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Competitive Landscape<\/h2>\n\n\n\n
Competitor<\/th>Product<\/th>Mechanism<\/th>China Status<\/th>Tenapanor Advantage<\/th><\/tr><\/thead>
Sanofi<\/strong><\/td>Renvela (sevelamer)<\/td>Phosphate binder (resin)<\/td>Generic available<\/td>Novel mechanism; reduced GI side effects<\/td><\/tr>
Fresenius<\/strong><\/td>Velphoro (sucroferric oxyhydroxide)<\/td>Iron-based phosphate binder<\/td>Approved<\/td>Oral convenience; different pathway<\/td><\/tr>
Akebia<\/strong><\/td>Auryxia (ferric citrate)<\/td>Iron-based binder + phosphate binder<\/td>Not in China<\/td>First-in-class NHE3 mechanism in market<\/td><\/tr>
Ardelyx\/Fosun<\/strong><\/td>Tenapanor<\/strong><\/td>NHE3 inhibitor<\/strong><\/td>Launched (March 2026)<\/strong><\/td>Unique MOA; addresses unmet need in binder failures<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Rationale & Mechanism<\/h2>\n\n\n\n
Parameter<\/th>Tenapanor Mechanism<\/th><\/tr><\/thead>
Target<\/strong><\/td>NHE3 on intestinal epithelial cells<\/td><\/tr>
Action<\/strong><\/td>Inhibits sodium\/hydrogen exchange \u2192 tightens tight junctions<\/td><\/tr>
Phosphate Effect<\/strong><\/td>Reduces paracellular (between-cell) phosphate absorption \u2013 primary intestinal phosphate uptake route<\/td><\/tr>
Serum Phosphorus<\/strong><\/td>Dose-dependent reduction; additive to binder therapy<\/td><\/tr>
GI Tolerability<\/strong><\/td>Diarrhea most common AE; generally manageable vs. binder GI burden<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward-Looking Priorities<\/h2>\n\n\n\n